TABLE 3.
Susceptibility profiles of ESBL-producing K. pneumoniae isolates, interpreted using 2010 and 2014 CLSI breakpoints
| Drug | No. (%) with CLSI interpretation of: |
||
|---|---|---|---|
| Sensitive | Intermediate | Resistant | |
| Aztreonam | 11 (4.8) | 5 (2.2) | 213 (93.0) |
| Cefotaxime | 0 (0) | 10 (4.4) | 219 (95.6) |
| Ceftazidime | 13 (5.7) | 8 (3.5) | 208 (90.8) |
| Ceftriaxone | 7 (3.1) | 2 (0.9) | 220 (96.1) |
| Cefuroxime | 8 (3.5) | 4 (1.7) | 217 (94.8) |
| Cefepime | |||
| 2010 breakpoints | 67 (29.3) | 20 (8.7) | 142 (62.0) |
| 2014 breakpoints | 67 (29.3)a | 162 (70.7) | |
a
Sensitive or sensitive dose dependent.